)
Mativ (MATV) investor relations material
Mativ Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 net sales were $499.5M, down 2.8% reported and 2.3% organically; adjusted EBITDA was $62.3M, down 6.7% YoY, with tornado disruption a primary sales headwind.
FAM delivered record sales growth and margin expansion, contrasting with SAS weakness from tornado disruption, Healthcare destocking and tariffs.
9M adjusted EBITDA rose 8% to $184.8M, adjusted EBITDA margin increased 100 bps to 12.2%, and free cash flow rose 5% to $90.5M.
Financial highlights
Q3 gross profit was $97.7M, down 1.7%; gross margin was 19.6% versus 19.3%, and operating profit rose 24.4% to $19.9M.
Q3 adjusted EBITDA was $62.3M, down 6.7%; adjusted EBITDA margin was 12.5%, down 50 bps YoY.
GAAP net loss narrowed to $1.2M from $3.2M; adjusted income was $17.5M and adjusted diluted EPS was $0.31 versus $0.39.
9M gross profit rose 7.3% to $295.9M; adjusted EBITDA was $184.8M versus $171.2M, and adjusted income was $49.6M versus $34.1M.
9M operating cash flow increased 3% to $117.4M and free cash flow increased 5% to $90.5M; capital spending was $26.9M.
Outlook and guidance
Q4 adjusted EBITDA is expected to be resilient and broadly stable, with low-single-digit-percent YoY moderation, mainly from temporary storm-recovery costs and North American tariffs.
Q4 organic volume growth is expected in both segments; October and November order pacing supported the outlook, with FAM films and filtration among growth drivers.
Full-year revenue, earnings and cash generation are expected to exceed 2025 levels; temporary headwinds are expected to ease for a stronger start to 2027.
Healthcare destocking is expected through year-end, with order patterns normalizing in early 2027; storm-related lost sales are expected to be largely recovered over the next couple of quarters.
Excess cash is directed to debt reduction, with the upper end of the 2.5–3.5x target leverage range expected by mid-2027.
- Destocking pressured Q4 results as synergies, restructuring and debt reduction supported 2024 priorities.MATV
Q4 2023 - Adjusted EBITDA up 12% with margin at 14.1% and strong free cash flow growth.MATV
Q2 2026 - All proposals passed, including director elections and equity plan amendment, with no questions raised.MATV
AGM 2026 - Adjusted EBITDA rose 28% to $47.5M, with margin gains and leverage reduced to 4.1x.MATV
Q1 2026 - Operational transformation and targeted investments drive growth and margin expansion.MATV
Investor presentation - Annual meeting to vote on directors, auditor, compensation, and equity plan amendment.MATV
Proxy Filing - Proxy covers director elections, auditor ratification, compensation, and equity plan amendment.MATV
Proxy Filing - Record free cash flow and EBITDA gains in 2025, despite a major goodwill impairment.MATV
Q4 2025 - SaaS/SAS growth and cost actions offset FAM headwinds, positioning for profit gains in 2025.MATV
Q4 2024
)
)
)
)
)
)
)
)